Questions around this news
What did the FDA say about the KETAFREE application?
NRx Pharmaceuticals said the FDA received the application and considered it “substantially complete.” The agency assigned a review goal date of July 29, 2026. That date is a target for the review, not an announcement that the drug has been approved; the release says sales in 2026 could follow if approval occurs on schedule.
What is an Abbreviated New Drug Application?
An Abbreviated New Drug Application, or ANDA, is a submission seeking approval to market a generic drug. It generally relies on the FDA’s prior finding that a reference drug is safe and effective, while providing information to establish that the proposed generic meets applicable requirements, such as sameness and manufacturing quality. The review process differs from a full application for a new drug.
How does KETAFREE differ from the NRX-100 program?
The release describes KETAFREE as a preservative-free intravenous ketamine formulation intended as a single-patient alternative to current multidose ketamine vials containing Benzethonium Chloride. It says the KETAFREE program is separate from NRX-100, which it identifies as a Fast Track-designated treatment for suicidal depression.
What does “substantially complete” mean in an FDA application review?
In general, the phrase indicates that an application has passed an initial completeness check and can proceed into substantive review. It does not mean the FDA has reached a decision on whether to approve the product. The agency may assess the evidence and information in the application before making that decision.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose ketamine vials that contain Benzethonium Chloride, a compound no longer recognized as safe by the FDA. The Company said KETAFREE aligns with MAHA initiatives to remove toxic substances from medicines and supports domestic supply-chain priorities, with potential 2026 approved drug sales if approved on schedule. NRx noted the program is separate from NRX-100, its Fast Track-designated treatment for suicidal depression, and said it continues to advance its broader pipeline and HOPE Therapeutics clinics.
To view the full press release, visit https://ibn.fm/OaRPK
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- NRx Pharmaceuticals, Inc.
- Ticker
- NASDAQ: NRXP
- Announcement
- Regulatory
Key figures
- FDA review goal date
- July 29, 2026
- Potential drug sales timing if approved on schedule
- 2026
People
- Jonathan JavittCEO
